(Q34986710)

5 August 2017

1 reference

title

Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents (English)

1 reference

5 August 2017

1 reference

James P Tsikouris

1

1 reference

5 August 2017

Jose A Suarez

series ordinal

2

1 reference

5 August 2017

Gary E Meyerrose

series ordinal

3

1 reference

5 August 2017

publication date

1 November 2002

1 reference

The Journal of Clinical Pharmacology

5 August 2017

published in

1 reference

5 August 2017

volume

42

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1187-1199

1 reference

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Coronary thrombosis: pathogenesis and clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Coronary Plaque Disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Regulation of Plasminogen Activator Production by Endothelial Cells: Role in Fibrinolysis and Local Proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The renin-angiotensin system and fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Impaired fibrinolysis in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Molecular bases of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The pathogenesis of atherosclerosis--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Tissue cooperation in a proteolytic cascade activating human interstitial collagenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Glucose tolerance in women: the effects of age, body composition, and sex hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Acute vascular effects of estrogen in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Systematic review on the risk and benefit of different cholesterol-lowering interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Hypertriglyceridemia and regulation of fibrinolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Relationship between fibrinolytic and metabolic variables: a study in patients attending a lipid clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Oral, but Not Transdermal, Administration of Estrogens Lowers Tissue-Type Plasminogen Activator Levels in Humans Without Affecting Endothelial Synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Changes in arterial expression of fibrinolytic system proteins in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Monocytic origin of foam cells in human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Bradykinin stimulates tissue plasminogen activator release in human vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Normal but not hypertriglyceridemic very low-density lipoprotein induces rapid release of tissue plasminogen activator from cultured human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The impact of female hormone usage on the lipid profile. The Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

New lipid lowering drugs and new effects of old drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491271

10.1177/009127002762491271

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference